All In Biotech

Drug Trial Radar · NCT06307652

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared With Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients With Heart Failure and Impaired Kidney Function

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 4,005 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

4,005

Actual

Start

Apr 12, 2024

Primary completion

Apr 16, 2027

Study completion Apr 16, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Mar 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event. The aim is to evaluate the effect of balcinrenone/dapagliflozin vs dapagliflozin, given once daily on top of other classes of SoC, on CV death and HF events.

Conditions

  • Heart Failure and Impaired Kidney Function

Interventions

  • balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mgDrug

    1 capsule of balcinrenone/dapagliflozin 15 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use

  • balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mgDrug

    1 capsule of balcinrenone/dapagliflozin 40 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use

  • dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozinDrug

    1 tablet of dapagliflozin 10 mg and 1 capsule of matching placebo for balcinrenone/dapagliflozin once daily, oral use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first occurrence of any of the components of the composite of: •CV death •HF hospitalisation •HF event without hospitalisationTime frame: Approximately 36 months

Locations

676 sites in 39 countries. Site status is shown where the registry gives one.

  • Research Site

    Alexander City, Alabama

  • Research Site

    Fairhope, Alabama

  • Research Site

    Huntsville, Alabama

  • Research Site

    Phoenix, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Beverly Hills, California

  • Research Site

    Covina, California

  • Research Site

    Encinitas, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Newport Beach, California

  • Research Site

    Redding, California

  • Research Site

    San Diego, California

  • Research Site

    San Francisco, California

  • Research Site

    San Francisco, California

  • Research Site

    Thousand Oaks, California

  • Research Site

    Vista, California

  • Research Site

    West Hills, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Wheat Ridge, Colorado

  • Research Site

    Altamonte Springs, Florida

  • Research Site

    Boca Raton, Florida

  • Research Site

    Bradenton, Florida

  • Research Site

    Delray Beach, Florida

  • Research Site

    Gainesville, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami Lakes, Florida

  • Research Site

    Safety Harbor, Florida

  • Research Site

    Saint Augustine, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Peachtree City, Georgia

  • Research Site

    Tucker, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Hazel Crest, Illinois

  • Research Site

    North Chicago, Illinois

Showing 40 of 676 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.